Subgroup analysis was performed with regard to the instillation drugs used after TUR, and the pooled results indicated that the high CD163+ TAMs density was associated with poor RFS in the bladder cancer patients treated with TUR followed by BCG instillation. The gene discussed is CD163; the disease is urinary bladder cancer.